Atomo Diagnostics (ASX:AT1) Total Liabilities: A$2.84 Mil (As of Dec. 2025)


What is Atomo Diagnostics Total Liabilities?

Atomo Diagnostics ASX:AT1 Total Liabilities is A$2.84 Mil as of Dec. 2025. The stock has 4 warning signs investors should review.

Atomo Diagnostics's Total Liabilities for the quarter that ended in Dec. 2025 was A$2.84 Mil.

Atomo Diagnostics's quarterly Total Liabilities increased from Dec. 2024 (A$1.84 Mil) to Jun. 2025 (A$2.30 Mil) and increased from Jun. 2025 (A$2.30 Mil) to Dec. 2025 (A$2.84 Mil).

Atomo Diagnostics's annual Total Liabilities declined from Jun. 2023 (A$1.68 Mil) to Jun. 2024 (A$1.35 Mil) but then increased from Jun. 2024 (A$1.35 Mil) to Jun. 2025 (A$2.30 Mil).

Atomo Diagnostics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Atomo Diagnostics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atomo Diagnostics Total Liabilities Chart

Atomo Diagnostics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Liabilities
Get a 7-Day Free Trial 2.15 1.81 1.68 1.35 2.30

Atomo Diagnostics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.23 1.35 1.84 2.30 2.84

Atomo Diagnostics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Atomo Diagnostics's Total Liabilities for the fiscal year that ended in Jun. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.166+(0.03+0.106
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=2.30

Total Liabilities=Total Assets (A: Jun. 2025 )-Total Equity (A: Jun. 2025 )
=9.277-6.976
=2.30

Atomo Diagnostics's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.511+(0.254+0.071
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=2.84

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=9.48-6.644
=2.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of A$2.84 Mil mean?
Atomo Diagnostics (ASX:AT1) has a Total Liabilities of A$2.84 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Atomo Diagnostics and its competitors.
Is Atomo Diagnostics' Total Liabilities too high?
Atomo Diagnostics' current Total Liabilities is A$2.84 Mil.
How does Atomo Diagnostics' Total Liabilities compare to ABT and SYK?
Atomo Diagnostics' Total Liabilities of A$2.84 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Devices & Instruments company?
A good Total Liabilities depends on the Medical Devices & Instruments industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Atomo Diagnostics and its competitors. Atomo Diagnostics's current Total Liabilities is A$2.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atomo Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Atomo Diagnostics (ASX:AT1) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.02 — trading 15% below its estimated fair value. The current Total Liabilities is A$2.84 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Atomo Diagnostics (ASX:AT1), the current Total Liabilities is A$2.84 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atomo Diagnostics Business Description

Address 3 - 5 George Street, Level 1, Leichhardt, Syndey, NSW, AUS, 2040
Atomo Diagnostics Ltd is an Australian medical device design innovator and original equipment manufacturing company. The company is engaged in the development and sale of medical devices. The company develops point-of-care devices for rapid diagnostic testing. The company offers AtomoRapid RDT Platform with devices including Galileo, Pascal, Curie, and Elion. The firm operates in a single segment, medical device research and development.